NEW YORK (GenomeWeb News) – Foundation Medicine and Ariad Pharmaceuticals today announced a deal aimed at the genomic profiling of patients enrolled in clinical trials for Ariad's investigational dual-inhibitor of ALK and EGFR for non-small cell lung cancer and other cancers.
The firms will collaborate on the generation of genomic profile information for patients enrolled in Ariad's ongoing Phase 1/2 trial for its drug AP26113, and data will be matched with clinical observations to better understand the activity and selectivity of the drug, Foundation and Ariad said.
Financial and other terms of the deal were not disclosed.
"This study is an example of how cancer complexity often defies single-marker analysis in drug development," Foundation President and CEO Michael Pellini said in a statement. "We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline."
On Monday the Cambridge, Mass.-based firm announced a deal with AstraZeneca to identify genomic mutations in cancer-related tumor genes.